Oppenheimer & CO Inc Abb Vie Inc. Transaction History

Oppenheimer & CO Inc

$6.18 Billion
Q2 2024

A detailed history of Oppenheimer & CO Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 153,622 shares of ABBV stock, worth $29.5 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares

153,622

Previous 150,363 2.17%

Holding current value

$29.5 Million

Previous $27.4 Million 3.77%

% of portfolio

0.43%

Previous 0.46%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$154.79 - $180.76 $504,460 - $589,096	3,259 Added 2.17%	153,622 $26.3 Million
Q1 2024 May 06, 2024	SELL	$159.82 - $182.1 $781,359 - $890,286	-4,889 Reduced 3.15%	150,363 $27.4 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $375,235 - $422,603	2,727 Added 1.79%	155,252 $24.1 Million
Q3 2023 Nov 07, 2023	SELL	$133.59 - $154.65 $332,906 - $385,387	-2,492 Reduced 1.61%	152,525 $22.7 Million
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $1.88 Million - $2.34 Million	-14,163 Reduced 8.37%	155,017 $20.9 Million
Q1 2023 May 10, 2023	BUY	$144.61 - $166.54 $1.41 Million - $1.62 Million	9,732 Added 6.1%	169,180 $27 Million
Q4 2022 Feb 07, 2023	SELL	$138.31 - $165.87 $230,009 - $275,841	-1,663 Reduced 1.03%	159,448 $25.8 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $776,404 - $890,485	-5,785 Reduced 3.47%	161,111 $21.6 Million
Q2 2022 Aug 08, 2022	SELL	$137.62 - $174.96 $1.22 Million - $1.55 Million	-8,876 Reduced 5.05%	166,896 $25.6 Million
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $1.35 Million - $1.67 Million	-10,200 Reduced 5.48%	175,772 $28.5 Million
Q4 2021 Feb 02, 2022	SELL	$107.43 - $135.93 $453,784 - $574,168	-4,224 Reduced 2.22%	185,972 $25.2 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $740,118 - $840,145	6,956 Added 3.8%	190,196 $20.5 Million
Q2 2021 Aug 03, 2021	BUY	$105.21 - $117.21 $17,464 - $19,456	166 Added 0.09%	183,240 $20.6 Million
Q1 2021 May 10, 2021	BUY	$102.3 - $112.62 $779,526 - $858,164	7,620 Added 4.34%	183,074 $19.8 Million
Q4 2020 Feb 11, 2021	SELL	$80.49 - $108.67 $278,495 - $375,998	-3,460 Reduced 1.93%	175,454 $18.8 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $7.74 Million - $9.09 Million	-90,130 Reduced 33.5%	178,914 $15.7 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $4.06 Million - $5.43 Million	55,313 Added 25.88%	269,044 $26.4 Million
Q1 2020 May 08, 2020	BUY	$64.5 - $97.79 $1.25 Million - $1.89 Million	19,360 Added 9.96%	213,731 $16.3 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $2.01 Million - $2.51 Million	27,860 Added 16.73%	194,371 $17.2 Million
Q3 2019 Oct 31, 2019	BUY	$62.98 - $75.72 $396,899 - $477,187	6,302 Added 3.93%	166,511 $12.6 Million
Q2 2019 Aug 09, 2019	BUY	$65.7 - $83.98 $2.11 Million - $2.7 Million	32,122 Added 25.08%	160,209 $11.7 Million
Q1 2019 Apr 24, 2019	SELL	$77.14 - $90.79 $4.78 Million - $5.63 Million	-61,994 Reduced 32.61%	128,087 $10.3 Million
Q4 2018 Jan 29, 2019	SELL	$77.85 - $96.01 $294,350 - $363,013	-3,781 Reduced 1.95%	190,081 $17.5 Million
Q3 2018 Oct 26, 2018	SELL	$88.91 - $98.84 $870,873 - $968,137	-9,795 Reduced 4.81%	193,862 $18.3 Million
Q2 2018 Aug 10, 2018	BUY	$89.78 - $106.23 $279,574 - $330,800	3,114 Added 1.55%	203,657 $18.9 Million
Q1 2018 May 01, 2018	SELL	$92.01 - $123.21 $2.16 Million - $2.9 Million	-23,504 Reduced 10.49%	200,543 $19 Million
Q4 2017 Feb 07, 2018	SELL	$89.56 - $98.21 $798,696 - $875,836	-8,918 Reduced 3.83%	224,047 $21.7 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $16.3 Million - $20.8 Million	232,965	232,965 $20.7 Million

Others Institutions Holding ABBV

# of Institutions

3,694

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $339B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Abb Vie Inc. Transaction History